细胞杂交技术及其应用

本文报告了1980年以来我们在细胞杂交技术及其应用研究中取得的各项阶段性成果。在细胞杂交技术方面,用分子量在1000、2000、4000、6000的PEG为融合介质,获得了中国仓鼠成纤维细胞Wg3-h、人HeLa细胞、人胃腺癌细胞SGC-T901的同种异核体,以及雄性麂肺细胞KIZ-7901-中国仓鼠成纤维细胞Wg3-h、中国仓鼠卵巢细胞CHO-人外周血港巴细胞、中国仓鼠卵巢细胞CHO-正常人骨髓细胞、中国仓鼠卵巢细胞CHO-白血病患者骨髓细胞的异种异核体,并成功地显示了上述各种细胞组合的PCC图象。获得了在体外长期传代培养的小鼠骨髓瘤细胞NS-1-Ag8-BALB／c小鼠脾脏淋巴细胞以及小鼠骨髓瘤细胞SP2／0-Ag14-免疫后的BALB／c小鼠脾脏淋巴细胞的种内杂种细胞系。在细胞杂交技术的应用方面,重点在诱导“熟前凝聚染色体”(PCC),分析白血病患者骨髓细胞的群体增殖潜能。并据以判断白血病患者病情进展、疗效和预后,以及制备分泌抗人C4单克隆抗体的杂交瘤细胞系。本文对PEG的融合性能、白血病患者PPI值升高的机制、杂交瘤细胞的亚克隆化等问题进行了初步探讨。

Cell hybridization techniques and of their some applications.

Cell hybridization was done by means of polyethylene glycol (PEG)in suspension.Seven kinds of heterokaryons showing pr- emature condensed chromosomes were obtained.A hybridoma cell line had been established which produced monoclonal anti- body anti human complement 4.On the basis of showing prem- ature condensed chromosomes of heterophasic heterokaryons between CHO metaphase cells and bone marrow lymphocytes from patients with leukemia,their potential proliferation index of bone marrow cell population was studied.Here also were discussed some items,the fusioninducing effects of PEG,the mechanism of the increase of leukemia patients'PPI and the subclioning of hybridoma cell line etc.